Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Testagen

Lys-Glu-Asp-Gly Gonadal Bioregulator

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Evidence rests on preclinical animal and cell-culture work from the Khavinson group plus a single small non-randomized Russian/Ukrainian clinical report; the peptide is listed as KEDG in the Molecules 2021 systematic review under regulation of male reproductive function, but no randomized controlled trial, dose-response study, or pharmacokinetic analysis exists and no Western trial is registered. The current grade of 2 and rcts of 2 are inflated, so grade 1 with 0 RCTs is the honest grade.

FDA
Not approved by the FDA for any indication; not evaluated by any Western regulator; no ClinicalTrials.gov registration; sold in the United States only as a research chemical labeled not for human use
WADA
Not listed on the WADA Prohibited List by name; no specific prohibition identified

Reference only. Not medical advice.

What can go wrong

Unapproved research chemical with human data limited to one non-randomized Russian/Ukrainian report; purity, dose, and long-term safety are uncharacterized in humans.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Testagen. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A Khavinson tetrapeptide targeting testicular gene expression and testosterone maintenance in aging men. Russian data only.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Male hormonal aging (Russian protocol)
  • Testosterone maintenance

How it is supposed to work

Testagen is a synthetic peptide bioregulator directed at the male reproductive system, promoted to support testicular and reproductive function in the Khavinson framework. Its tissue-specific mechanism is unproven in rigorous human studies.

Testagen is a synthetic short peptide, a defined-sequence second-generation bioregulator aimed at reproductive tissue, part of the same organ-by-organ system as the other Khavinson peptides.

Type
Synthetic short peptide
Target
Testes and reproduction
Generation
Second (defined)
Use
Pulsed courses
Evidence
Preclinical and Russian
Western RCT
None

The Reproductive Label On A Single-Lineage Peptide System

Testagen follows the family template without exception. Its proposed mechanism is direct peptide-driven gene regulation in reproductive tissue, unestablished outside the originating group, and its claims are preclinical and Russian with no independent human trials. It is one more tissue-labeled member of a single-lineage system, here aimed at a hormonal domain where proper endocrine evaluation, not a gray-market peptide, is the appropriate route for real concerns.

Safety in detail

Human safety is essentially uncharacterized: no RCT, no pharmacokinetic study, and no regulatory review support any dose or route, and vendor material is sold for research use only rather than as a medicine.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Testagen has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use, and reproductive-targeted compounds are especially inappropriate for minors.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Testagen reaches users only through the bioregulator gray market and longevity vendors, with no approved product.

How we got here

Testagen originates in Vladimir Khavinson's program at the St. Petersburg Institute of Bioregulation and Gerontology, which first isolated organ-specific peptide fractions from animal tissue (the natural cytamin extracts, the testicular one being Testoluten) and then reduced them to defined synthetic ultrashort peptides (the cytogens). Testagen is the synthetic KEDG tetrapeptide assigned to the testis, and its activity of regulating male reproductive gene expression is recorded under the KEDG sequence in the group's Molecules 2021 systematic review. Unlike the six Khavinson peptides that reached pharmaceutical registration in Russia, Testagen was never registered as a drug and today circulates as a Russian dietary-supplement peptide and, in Western markets, as a not-for-human-consumption research chemical sold by peptide vendors. It shares three residues with Chonluten (EDG), and the two are sometimes conflated in vendor copy, so its identity is best pinned to the full KEDG code.

Testagen was developed as a defined-sequence organ bioregulator at the St. Petersburg institute, extending Khavinson’s approach to male reproductive tissue.

The numbers behind the grade

Type
Reproductive peptide
Target
Male reproductive system
Russia
Bioregulator line
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

A reproductive-system bioregulator with a small niche following.

Testagen’s users are men focused on reproductive and hormonal aging within the longevity and bioregulator-protocol community.

Used as a reproductive-support bioregulator within Russian-tradition protocols; not independently validated.

Set against the alternatives

Testagen is the reproductive counterpart in the same system as the prostate peptide Prostamax, sharing the family’s framing applied to male reproductive tissue. Its support is preclinical and single-lineage, unlike evidence-based endocrinology.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Testagen.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group studies2000s

    Reported reproductive-tissue effects within the bioregulator literature.

  • Independent replicationnone notable

    No independent Western trials of Testagen exist.